Krystal Biotech Files 8-K
Ticker: KRYS · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1711279
| Field | Detail |
|---|---|
| Company | Krystal Biotech, Inc. (KRYS) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Krystal Biotech filed a routine 8-K on 12/18/24. Check exhibits for news.
AI Summary
Krystal Biotech, Inc. filed an 8-K on December 18, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond its routine reporting nature.
Why It Matters
This filing indicates Krystal Biotech is meeting its regulatory reporting obligations. Investors should review the exhibits for any material updates.
Risk Assessment
Risk Level: low — This is a routine SEC filing with no new material information disclosed.
Key Players & Entities
- Krystal Biotech, Inc. (company) — Registrant
- December 18, 2024 (date) — Date of Report
- 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on December 18, 2024.
What is Krystal Biotech, Inc.'s principal executive office address?
Krystal Biotech, Inc.'s principal executive offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania 15203.
What is Krystal Biotech, Inc.'s state of incorporation?
Krystal Biotech, Inc. is incorporated in Delaware.
What is Krystal Biotech, Inc.'s IRS Employer Identification Number?
Krystal Biotech, Inc.'s IRS Employer Identification Number is 82-1080209.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-12-18 08:39:33
Filing Documents
- krys-20241218.htm (8-K) — 32KB
- cancerdataannouncementfinal.htm (EX-99.1) — 17KB
- 0001711279-24-000065.txt ( ) — 167KB
- krys-20241218.xsd (EX-101.SCH) — 2KB
- krys-20241218_lab.xml (EX-101.LAB) — 20KB
- krys-20241218_pre.xml (EX-101.PRE) — 11KB
- krys-20241218_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 18, 2024, Krystal Biotech, Inc. (the "Company") issued a press release announcing initial clinical results from its ongoing KYANITE-1 study evaluating inhaled KB707 in patients with solid tumors of the lung demonstrating early evidence of monotherapy activity in heavily pre-treated patients with advanced non-small cell lung cancer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto shall not be (i) deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, or (ii) incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 18, 2024 104 Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 18, 2024 KRYSTAL BIOTECH, INC. By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer